ShilpaMedicare has received approval from U.S Food and Drug Administration (USFDA)for Varenicline Tablets, 0.5 and 1 mg. The total US market for this product isaround $203 million.
Thecompany’s product has been approved as a generic version to the innovator -Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism). VareniclineTablets are indicated for smoking cessation; it helps people to quit smoking.
ShilpaMedicare produces and exports consistently high-quality Active PharmaceuticalIngredients Fine Chemicals, intermediates, herbal products and specialitychemical products using sophisticated technology, meticulously followinginternational specifications.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: